KPIs & Operating Metrics(New)
Growth Metrics

Charles River Laboratories International (CRL) Non-Current Deferred Tax Liability (2016 - 2025)

Charles River Laboratories International has reported Non-Current Deferred Tax Liability over the past 14 years, most recently at $95.2 million for Q4 2025.

  • For Q4 2025, Non-Current Deferred Tax Liability fell 10.99% year-over-year to $95.2 million; the TTM value through Dec 2025 reached $95.2 million, down 10.99%, while the annual FY2025 figure was $95.2 million, 10.99% down from the prior year.
  • Non-Current Deferred Tax Liability for Q4 2025 was $95.2 million at Charles River Laboratories International, down from $123.0 million in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $420.6 million in Q4 2021 and troughed at $95.2 million in Q4 2025.
  • A 5-year average of $193.6 million and a median of $193.7 million in 2022 define the central range for Non-Current Deferred Tax Liability.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: surged 30.12% in 2021 and later tumbled 48.74% in 2022.
  • Year by year, Non-Current Deferred Tax Liability stood at $420.6 million in 2021, then tumbled by 48.74% to $215.6 million in 2022, then decreased by 11.24% to $191.3 million in 2023, then tumbled by 44.1% to $107.0 million in 2024, then dropped by 10.99% to $95.2 million in 2025.
  • Business Quant data shows Non-Current Deferred Tax Liability for CRL at $95.2 million in Q4 2025, $123.0 million in Q3 2025, and $109.3 million in Q2 2025.